Form 4 Edwards Lifesciences For: Feb 01 Filed by: Ullem Scott B.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Edwards Lifesciences (EW) shares rally on Evoque FDA approval
February 2, 2024 11:26 AM ESTEdwards Lifesciences (NYSE: EW) shares are rallying Friday after the companys EVOQUE tricuspid valve replacement system was approved by the U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
EW shares are up more than 7% at $84.50 per share at the... More
